louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05377931: Ocular and Cardiac Effects of Battle Ground
Official title: Ocular and Cardiac Effects of Mobile Battle Ground Games
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID-19
Accommodation Spasm
Tachycardia
Stress Reaction
Cardiac Arrhythmia
Keywords: Battle ground games
Accommodation
Spasm
Eye strain
Pulse disorder
Tachycardia
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2022-05-17
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects that are using action mobile games during their leisure and are members of faculty of medicine, Banha university and are seeking to participate in this study.

Brief summary: Mobile battle ground games are widely used in various age groups, there are ocular and cardiac affection that may affect users of this type of action games.

Detailed description: The aim of this study is to assess the possible ocular and cardiac changes that may affect users of this type of mobile games in real life among various age groups and especially in adults with history of recent corona virus (COVID-19) disease. There is no medical recommendations about the time and the hazards of using this games for longer periods in real practice.

Eligibility criteria: Inclusion Criteria:

* Normal subjects that are playing or not playing action mobile battle ground games will be included.
* Post COVID-19 subjects with average 6 months of infection and are playing mobile battle. Ground games will be included.

Exclusion Criteria:

* Subjects that refuse to enter the study.
* Users of mobile battle ground games with other diseases that may affect ocular and cardiac assessment as diabetic eye disease, cardiac congenital anomalies or recent cardiac or ocular surgery.

Primary outcomes:
measure: Changes in heart pulse rate
timeFrame: During playing mobile battle ground games
Secondary outcomes:
measure: Changes in accommodation
timeFrame: Before and immediately after mobile battle ground games
Other outcomes:
Locations:
city: Banhā
country: Egypt
facility: Ahmed Abdelshafy
state: QA
Study officials:
affiliation: Benha University
name: Mohamed A Abdelshafy, MD
role: STUDY_CHAIR
References:
Clinical trial NCT02885831: Early Abduction Splintage on Stable Hips in Infants With Developmental Dysplasia of the Hip
Official title: Early Abduction Splintage on Stable Hips in Infants With Developmental Dysplasia of the Hip : Improvement or Overtreatment ?
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Congenital Hip Dysplasia
Keywords: Abduction splint
Pubo-femoral distance
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2016-09-01
Enrollment: 90
Sex: ALL
Minimum age (years): 1
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Infants who underwent ultrasonographic screening for developmental dysplasia of the hip and are adressed to a paediatric orthopaedic surgeon at Brest University Hospital.

Brief summary: The aim of this study is to prove the improvement of pubo-femoral distance by early abduction splintage in one-month-old infants with developmental dysplasia of the hip (with a clinical stable hip but an abnormal hip ultrasonography).


Eligibility criteria: Inclusion Criteria:

* Term infants
* Infants between 1 and 2 months of age at inclusion
* Clinically stable hip
* Pathological ultrasonography : pubo-femoral distance \>6mm and bony rim percentage \<50%
* Non objection of the family

Exclusion Criteria:

* Clinically unstable hip
* Normal ultrasonography
* Neuro-orthopedic disease
* Postural deformity of the pelvis
* Participation refusal

Primary outcomes:
measure: Normal or abnormal hip ultrasound
timeFrame: 2 months
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
Study officials:
affiliation: University Hospital, Brest
name: Matthias THEPAUT, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dwan K, Kirkham J, Paton RW, Morley E, Newton AW, Perry DC. Splinting for the non-operative management of developmental dysplasia of the hip (DDH) in children under six months of age. Cochrane Database Syst Rev. 2022 Oct 10;10(10):CD012717. doi: 10.1002/14651858.CD012717.pub2.
Clinical trial NCT04973631: The Effects of Sex and Age Differences on Gastric Cancer : a Retrospective Study
Official title: The Effects of Sex and Age Differences on Gastric Cancer in Terms of Incidence of Histologic Subtypes and Survival Rate: a Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sex
Age
Gastric Cancer
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
First posted: 2021-07-22
Enrollment: 14900
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients diagnosed with Gastric cancer at the Seoul National University Bundang Hospital were analyzed retrospectively from May 2003 to February 2020. The data were collected using clinical data warehouses (CDW), and electronic medical records (EMR) were reviewed as needed.

Brief summary: Gastric cancer (GC) is more prevalent in males than in females. One of these differences could be the effect of sex hormones such as estrogens. However, few reports have been reported regarding sex and age differences of incidence and survival of GC. The aim of this study was to evaluate the effect of sex and age on the incidence and survival of GC. And we would like to further analyze single GC and synchronous multiple GC, EBV, etc.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Gastric cancer

exclusion criteria:

* Gastric MALTOMA
* Gastric Lymphoma
* Gastrointestinal stromal tumors (GISTs)

Primary outcomes:
measure: Survival rate
timeFrame: up to 120 months
measure: histologic type
timeFrame: about 18 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Jo HH, Kim N, Jang J, Choi Y, Park J, Park YM, Ahn S, Yoon H, Shin CM, Park YS, Lee DH, Oh HJ, Lee HS, Park YS, Ahn SH, Suh YS, Park DJ, Kim HH, Kim JW, Kim JW, Lee KW, Chang W, Park JH, Lee YJ, Lee KH, Kim YH. Impact of Body Mass Index on Survival Depending on Sex in 14,688 Patients with Gastric Cancer in a Tertiary Hospital in South Korea. Gut Liver. 2023 Mar 15;17(2):243-258. doi: 10.5009/gnl220104. Epub 2022 Nov 1.
Clinical trial NCT05372731: Recruitment Maneuver After Bronchoalveolar Lavage in ARDS Patients
Official title: Recruitment Maneuver After Bronchoalveolar Lavage in ARDS Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Acute Respiratory Distress Syndrome
Lead sponsor: Southeast University, China
Sponsor class: OTHER
First posted: 2022-05-13
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: ARDS caused by pneumonia is one of the main reasons for ICU admission in critically ill patients, and also a common complication in patients admitted to ICU with invasive mechanical ventilation. Bronchoalveolar lavage (BAL) is the main diagnostic method for these patients, which often leads to alveolar collapse and exacerbates hypoxemia. In clinical practice, recruitment maneuver (RM) is often used immediately after BAL to prevent such a situation, but there is a lack of data on RM after BAL.


Eligibility criteria: Inclusion Criteria:

1. Adult patients with invasive mechanical ventilation;
2. Patients who diagnosed with ARDS according to the Berlin definition
3. There are indications for bronchoalveolar lavage

Exclusion Criteria:

1. Patients with contraindications for EIT procedures;
2. Patients with contraindications for RM;
3. Previous chronic respiratory diseases (long-term home oxygen therapy for chronic respiratory diseases such as pulmonary fibrosis or COPD);
4. Pregnancy;
5. Refusal to sign informed consent

Primary outcomes:
measure: the ratio of tidal volume in the BAL side and the other side
timeFrame: up to 24 hours
Secondary outcomes:
measure: partial pressure of arterial oxygen (Pao2) to the fraction of inspired oxygen (Fio2) ratio
timeFrame: up to 24 hours
measure: respiratory system compliance (the tidal volume to the driving pressure ratio)
timeFrame: up to 24 hours
Other outcomes:
Locations:
Study officials:
affiliation: Zhongda Hospital
name: ling liu, phD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01337531: Recombinant Versus Highly Purified FSH in Polycystic Ovary Syndrome (PCOS)
Official title: Recombinant FSH Versus Highly Purified FSH in PCOS Patients Undergoing Control Ovarian Stimulation and IVF: a Prospective Randomized Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Polycystic Ovary Syndrome
Keywords: Ovarian Response in PCOS
pregnancy rate in PCOS
miscarriage rate in PCOS
Lead sponsor: Genesis Center for Fertility & Human Pre-Implantation Genetics
Sponsor class: OTHER
First posted: 2011-04-19
Enrollment: 200
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Control ovarian stimulation responses, pregnancy and miscarriage rates are indifferent when either recombinant or highly purified follicle stimulating hormone (FSH) is used.

Detailed description: Patients will be randomized using sealed and numbered envelopes and will be assigned to receive a similar ovarian stimulation regime incorporating either Gonal-F or highly purified Fostimon as the hormonal analog. Ovarian response using either of the two compounds, pregnancy rates and miscarriage rates will be compared to define possible statistical significance.

Eligibility criteria: Inclusion Criteria:

* PCOS
* Primary infertility
* No other fertility manifestation

Exclusion Criteria:

* Non PCOS
* Secondary infertility

Primary outcomes:
measure: Ovarian Response
timeFrame: 0-15 days post gonadotropin administration
Secondary outcomes:
measure: Pregnancy rate
timeFrame: 12-15 days post embryo replacement
Other outcomes:
Locations:
city: Limassol
country: Cyprus
facility: Genesis Centre for Fertility and Human Pre-implantation Genetics
Study officials:
affiliation: Genesis Center for Fertility and Human Pre-implantation Genetics
name: Savvas N Koundouros, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06012331: Clinical and Radiographic Evaluation of Revascularization of Immature Anterior Permanent Teeth Using Concentrated Growth Factor (CGF) Versus Blood Clot (BC)
Official title: Clinical and Radiographic Evaluation of Revascularization of Immature Anterior Permanent Teeth Using (CGF) Versus (BC)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Revascularization
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-08-25
Enrollment: 50
Sex: ALL
Minimum age (years): 8
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to compare clinical and radiographic evaluation treatment of necrotic immature permanent teeth using:

1. Concentrated Growth Factor
2. Blood Clot

Detailed description: Rationale for conducting the research:

Concentrated growth factor (CGF) is relatively a new generation of platelet concentrate product, it contains more cytokines and growth factors compared with PRP and PRF also promotes the proliferation, migration, and differentiation of stem cells.

Eligibility criteria: Inclusion Criteria:

1. Children aged between 8_14 years.
2. Anterior tooth diagnosed with necrotic pulp (due to trauma, caries, or anomaly) responded negatively to sensibility tests.
3. Teeth not indicated for post and core.
4. A cooperative and compliant patient/parent.
5. Patients not allergic to medicaments necessary to complete the procedure.
6. Patients with no history of chronic systemic diseases.

Exclusion Criteria:

1. Medically compromised patient.
2. Teeth with vertical fractures.
3. Non-restorable teeth.
4. Teeth when bleeding could not be induced.
5. Unable to attend follow-up visits.

Primary outcomes:
measure: clinically successful treatment
timeFrame: 3,6,9,12 months
Secondary outcomes:
measure: Radiographic Success treatment
timeFrame: 6, 12 months
Other outcomes:
Locations:
Study officials:
References:
citation: Kasprisin DO, Heiss R, Rausen AR. Cholelithiasis during remission of acute lymphocytic leukemia in a child. Clin Pediatr (Phila). 1981 Oct;20(10):678. No abstract available.
citation: Ruskin KJ, Tissot M. A new method of communication between anesthesiologists. Anesthesiology. 1993 Oct;79(4):867. doi: 10.1097/00000542-199310000-00037. No abstract available.
Clinical trial NCT02381431: Use of Mobile Phones for Thermal Imaging of the Chest to Save Lives of Children With Pneumonia in Nagpur, India
Official title: Use of Mobile Phones for Thermal Imaging of the Chest to Save Lives of Children With Pneumonia in Nagpur, India
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Infections - Bacterial
Pneumonia - Bacterial
Keywords: imaging
diagnostic
pediatrics
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
Collaborators: name: Lata Medical Research Foundation, Nagpur
First posted: 2015-03-06
Enrollment: 75
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The purpose of this study is to see if thermal images can be used instead of a chest x-ray to diagnose bacterial pneumonia in children with signs and symptoms of pneumonia in Nagpur, India. More specifically, the objectives of the study are: 1) to determine if thermal imaging, using a commercial thermal camera can accurately detect the presence of bacterial pneumonia in children receiving a chest x-ray to rule out pneumonia; 2) to evaluate the use of thermal imaging to monitor the course and resolution of pneumonia in children diagnosed with pneumonia; and 3) to determine if thermal imaging can accurately diagnose sites of infection that are suspected to be related to the pneumonia.


Eligibility criteria: Inclusion Criteria:

* 18 years or younger
* patient at DAGA Memorial Hospital, Nagpur, India
* had chest x-ray within last 24 hours
* consent obtained from one parent
* assent obtained if child is 8 years or older

Exclusion Criteria:

* thermal image cannot be done within 24 hours of chest x-ray

Primary outcomes:
measure: diagnosis of bacterial pneumonia
timeFrame: 24 hours
Secondary outcomes:
measure: diagnosis of additional site of infection possibly related to bacterial pneumonia
timeFrame: within same hospital stay
Other outcomes:
Locations:
city: Nagpur
country: India
facility: DAGA Memorial Hospital
state: Maharashtra
Study officials:
affiliation: Massachusetts General Hospital
name: Patricia L Hibberd, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00588731: Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
Official title: Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Schizophrenia
Schizoaffective Disorder
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: Stanley Medical Research Institute
First posted: 2008-01-09
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.


Eligibility criteria: Inclusion Criteria:

* Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),

Exclusion Criteria:

* Women who are pregnant, nursing or unwilling to use appropriate birth control measures during study participation.

Primary outcomes:
measure: Verbal Short Term Memory
timeFrame: 6 weeks
Secondary outcomes:
measure: Overall Cognition as Measured on the MATRICS Battery
timeFrame: 6 weeks
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University
state: Connecticut
Study officials:
affiliation: Yale University
name: Mohini Ranganathan, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology (Berl). 2018 Jul;235(7):1923-1932. doi: 10.1007/s00213-018-4885-9. Epub 2018 Apr 5.
Clinical trial NCT02018731: L-citrulline and Metformin in Becker's Muscular Dystrophy
Official title: Pilot Study to Assess the Efficacy of L-Citrulline and Metformin in Adults With Becker's Muscular Dystrophy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Becker's Muscular Dystrophy (BMD)
Keywords: Becker's Muscular dystrophy
BMD
Metformin
L-citrulline
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2013-12-23
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to compare the effects of L-citrulline and metformin and their combination therapy on muscle function and force in patients with Becker muscular dystrophy (BMD).

Detailed description: This is a single center, not-randomized open study. The study medication consists of L-citrulline and metformin administered orally; 5g citrulline and 500mg metformin tablets will be given 3 times daily.

Half of the patients will be treated with metformin during the first 6 weeks of the study. The other patients will receive initially L-citrulline for 6 weeks, before all patients will be treated with the combination therapy (metformin and L-citrulline) for another 6 week period.

The study lasts 12 weeks and includes the screening visit and 3 further visits at baseline, week 6 and week 12.

Eligibility criteria: Inclusion Criteria:

* 18 years or older
* Molecular or immunohistochemical diagnosis of BMD
* ambulant at the time point of screening

Exclusion Criteria:

* Participation in another therapeutic BMD study within the last 3 months
* Use of L-Arginine, L-Citrulline or Metformin within the last 3 months
* Other chronic disease or relevant limitation of renal, liver, heart function according to discretion of investigator
* known hypersensitivity to L-citrulline or metformin

Primary outcomes:
measure: Mean change of motor function measure (MFM) D1 subscore after 6 and 12 weeks
timeFrame: week 6 and week 12
Secondary outcomes:
measure: MFM total score and six minute walking distance (6MWD)
timeFrame: week 6 and week 12
measure: Change of muscle fat content (MFC) (assessed by MRI)
timeFrame: week 6 and week 12
measure: Change of muscle metabolism (assessed by dual energy x-ray absorptiometry (DEXA) and indirect calorimetry)
timeFrame: week 6 and week 12
measure: Change of laboratory parameters (oxidative and nitrosative stress)
timeFrame: week 6 and week 12
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: University Children's Hospital
state: BS
Study officials:
affiliation: University Children's Hospital Basel
name: Dirk Fischer, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05673031: 68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
Official title: 68Ga-HA-DOTATATE PET/CT in Adults With Neuroendocrine Tumors
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Neuroendocrine Tumors (NET)
Lead sponsor: Alberta Health services
Sponsor class: OTHER
First posted: 2023-01-05
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine Tumor. Patients greater than 18 years of age who are able to follow instructions and provide written consent to participate in study.

Brief summary: To determine if 68Ga-HA-DOTATATE PET/CT imaging is effective at diagnosing somatostatin positive tumors compared to conventional imaging \[including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available\]

Detailed description: The purpose of the current study will be to evaluate the usefulness of 68Ga-HA-DOTATATE compared to current standard anatomical imaging including CT, MRI, 111 In-pentetreotide Scans, 18F-FDG PET/CT, as available. Specifically, we aim to assess the utility of 68Ga-HA-DOTATATE in primary workup of neuroendocrine tumours, including suspected neuroendocrine tumours that do not have a cross-sectional imaging correlate. An additional aim is to assess the role of 68Ga-HA-DOTATATE in surveillance of completely resected neuroendocrine tumours, which is a point of disagreement amongst current society guidelines . Finally, we will assess utility of 68Ga-HA-DOTATATE for localization of functioning neuroendocrine tumors including insulinoma and gastrinoma.

Eligibility criteria: Inclusion Criteria:

1. Male or female. If female of child-bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test will be required.
2. Age greater than or equal to 18 years.
3. Able and willing to follow instructions and comply with the protocol.
4. Provide written informed consent prior to participation in the study.
5. Clinically suspected (patients presenting with symptom(s) suggestive of carcinoid syndrome or biochemically suggestive of Neuroendocrine Tumor) or Biopsy proven Neuroendocrine Tumor

Exclusion Criteria:

1. Nursing or pregnant females.
2. Age less than 18 years.
3. Surgery in the area of interest within the preceding 2 months.

Primary outcomes:
measure: 68Ga-HA-DOTATATE PET/CT imaging
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Calgary
country: Canada
facility: Foothills Medical Center 1403 29 St NW
state: Alberta
Study officials:
References: